| __timestamp | Merck & Co., Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 16768000000 | 60987000 |
| Thursday, January 1, 2015 | 14934000000 | 125542000 |
| Friday, January 1, 2016 | 13891000000 | 210460000 |
| Sunday, January 1, 2017 | 12775000000 | 275119000 |
| Monday, January 1, 2018 | 13509000000 | 409539000 |
| Tuesday, January 1, 2019 | 14112000000 | 547758000 |
| Wednesday, January 1, 2020 | 13618000000 | 736300000 |
| Friday, January 1, 2021 | 13626000000 | 904200000 |
| Saturday, January 1, 2022 | 17411000000 | 1080300000 |
| Sunday, January 1, 2023 | 16126000000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Data in motion
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. Over the past decade, Merck & Co., Inc. and Vertex Pharmaceuticals have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Merck's cost of revenue fluctuated, peaking in 2022 with a 27% increase from its lowest point in 2017. Meanwhile, Vertex Pharmaceuticals demonstrated a remarkable upward trend, with its cost of revenue surging by over 1,900% from 2014 to 2023. This stark contrast highlights Vertex's aggressive growth strategy, while Merck's larger scale reflects its established market presence. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the operational efficiencies and strategic priorities of these industry leaders.
Cost of Revenue: Key Insights for Johnson & Johnson and Vertex Pharmaceuticals Incorporated
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Analyzing Cost of Revenue: Merck & Co., Inc. and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and PTC Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Merck & Co., Inc. and Dyne Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Novartis AG vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs BeiGene, Ltd.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Expenses
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Geron Corporation's Expenses
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.